$RXRX News

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?

Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone

Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?

Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions

Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone

Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today?

Recursion: Maintaining 'Hold' On REC-4881 End 2026 Program Update And Collaboration Candidates In Play

Recursion Pharmaceuticals: Sanofi News And Fundraising Sum Up Flawed Bull Thesis

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027

Recursion Commences $200M Common Stock Offering Of 61,540,000 Shares Of Its Class A Common Stock At A Price Of $3.25/Share

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors